Vinay Prasad

Dark and dramatic sky with sunlight
Biotech

After 'complete standstill,' biotech market reaches new normal

The first half of 2025 was brutal for biotech, but investors are still keen on therapeutics in several areas, such as cardiorenal and neuropsych.
Gabrielle Masson Aug 20, 2025 11:04am
clock delay wait time alarm

Regenxbio's Hunter gene therapy latest to face FDA delay

Aug 19, 2025 10:30am
FDA
Favicon Fierce Pharma

Vinay Prasad is back at the FDA after last month's surprise ouster

Aug 9, 2025 12:22pm
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
FDA
Favicon Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am
FDA
Favicon Fierce Pharma

FDA investigates 2 deaths after Sarepta Duchenne gene therapy

Jun 25, 2025 10:26am